Royal Caribbean Group (RCL) reported strong fourth-quarter results, meeting revenue expectations with a 13.3% year-over-year increase to $4.26 billion. The cruise giant's performance, driven by record passenger volumes and strategic investments, signals robust health in the leisure travel sector.
The business services sector has outperformed, riding a wave of corporate demand for efficiency. But with economic sensitivity looming, we analyze two companies with robust models and one where caution may be warranted.
Israel announces a limited reopening of the Rafah border crossing between Gaza and Egypt this Sunday, permitting the movement of people under strict security protocols for the first time since its capture in May 2024.
Secretary-General António Guterres warns the United Nations could exhaust its regular budget cash by July, citing chronic non-payment of dues by member states and a "Kafkaesque" financial cycle that threatens its core operations.
The parent company of numerous restaurant chains will be removed from the Nasdaq exchange on February 4, transitioning to high-risk over-the-counter trading after failing to meet listing requirements.
Silver prices plunged by a record 30% in a single session after President Trump nominated former Fed Governor Kevin Warsh to lead the central bank, a move seen as tempering expectations for aggressive rate cuts and bolstering the dollar.
ARK Invest's Cathie Wood made a significant $26 million investment in Broadcom stock last week, highlighting a strategic pivot towards AI infrastructure amid portfolio reshuffling. The move follows Broadcom's blockbuster earnings and comes as Wall Street maintains a bullish outlook on the chipmaker.
Despite a challenging year that saw Nike's shares fall sharply, a majority of analysts maintain a cautiously optimistic outlook, betting on the sportswear giant's long-term brand strength and innovation pipeline to fuel a recovery.
Footwear giant Deckers Brands posted quarterly revenue and profit that handily beat Wall Street estimates, driven by surging global demand for its HOKA and UGG labels. The company raised its full-year outlook, citing robust direct-to-consumer growth and international momentum.
CNBC's Jim Cramer suggests Intel shares could surge significantly, as the chipmaker's strategic overhaul and analyst upgrades fuel investor optimism amid a 140% yearly gain.
Shares of Deckers Outdoor surged over 17% Friday after the footwear and apparel company reported robust Q3 earnings, driven by full-price selling across its UGG and HOKA brands and prompting an upward revision to its annual forecast.
USA Rare Earth Inc. (NASDAQ: USAR) sees its price target significantly raised by Canaccord Genuity and Benchmark following a landmark $1.6 billion commitment from the U.S. CHIPS Program, accelerating its plans to build a domestic rare earth supply chain.
Amid a broader leadership restructuring, financial giant Charles Schwab has appointed its CIO, Dennis Howard, to lead a consolidated unit overseeing technology, operations, and data, signaling a strategic shift to deepen the integration of IT with core business functions.
Analyst firm Clear Street has raised its price target for Critical Metals Corp. (CRML) to $20, citing a strategic joint venture with a Saudi industrial group to build a rare earth processing facility. The move aims to diversify supply chains away from China and support Western defense needs.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.
Investment firm Maxim Group reaffirms its Buy rating and $1.50 price target for Strive Inc., following the company's transformative acquisition of Semler Scientific, which positions it as a major corporate Bitcoin holder and expands its healthcare tech footprint.
Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.
Michigan's Attorney General has formally demanded the return of state funds from Gotion Inc., a Chinese battery manufacturer, following the collapse of its planned $2.4 billion facility. The move highlights growing tensions over foreign investment in U.S. strategic industries.
